AQR Capital Management LLC Cuts Stock Position in Agenus Inc. (NASDAQ:AGEN)

AQR Capital Management LLC decreased its position in shares of Agenus Inc. (NASDAQ:AGEN) by 98.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,425 shares of the biotechnology company’s stock after selling 1,173,911 shares during the period. AQR Capital Management LLC owned 0.07% of Agenus worth $258,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new position in shares of Agenus during the second quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Agenus during the 2nd quarter worth $106,000. Blair William & Co. IL acquired a new position in Agenus during the 2nd quarter valued at about $441,000. Squarepoint Ops LLC purchased a new stake in Agenus in the second quarter valued at about $614,000. Finally, Ovata Capital Management Ltd acquired a new stake in Agenus in the second quarter worth about $670,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Price Performance

NASDAQ AGEN opened at $4.57 on Friday. Agenus Inc. has a 1 year low of $4.18 and a 1 year high of $23.00. The company has a market capitalization of $95.97 million, a PE ratio of -0.36 and a beta of 1.37. The company has a fifty day moving average of $5.18 and a 200 day moving average of $9.35.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The firm had revenue of $23.51 million during the quarter, compared to analyst estimates of $64.73 million. During the same period in the previous year, the business posted ($4.00) earnings per share. Research analysts expect that Agenus Inc. will post -10.87 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AGEN shares. HC Wainwright downgraded shares of Agenus from a “buy” rating to a “neutral” rating and cut their price objective for the company from $40.00 to $9.00 in a report on Thursday, July 18th. StockNews.com cut shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. William Blair lowered shares of Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. Robert W. Baird downgraded Agenus from an “outperform” rating to a “neutral” rating and cut their target price for the company from $35.00 to $8.00 in a research report on Friday, July 19th. Finally, B. Riley lowered their price target on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Agenus has an average rating of “Hold” and a consensus target price of $10.50.

Agenus Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.